Flatiron Health Highlights Real-World Oncology Data at ASCO GU 2026 — Flatiron Health, Inc.

Event summary

Flatiron Health presents six research studies at the ASCO GU 2026 Symposium in San Francisco, focusing on genitourinary cancers.
Panoramic datasets include over 420,000 longitudinal patient records across Germany, UK, and US for prostate and bladder cancer research.
Studies highlight gaps in genetic testing, treatment access, and post-Lu177 therapy options for advanced prostate cancer patients.
Research emphasizes real-world outcomes for cisplatin-ineligible bladder cancer patients and disparities in FGFR3 testing.

The big picture

Flatiron Health's participation at ASCO GU 2026 underscores the growing importance of real-world data in oncology research. The company's Panoramic datasets enable cross-market analysis, addressing critical gaps in treatment access and outcomes for genitourinary cancers. This aligns with broader industry trends toward personalized medicine and data-driven clinical decision-making.

What we're watching

Data Interoperability: The pace at which Flatiron's Panoramic datasets can drive global evidence strategies across different markets.
Treatment Access: How Flatiron's research will influence broader genetic testing and equitable access to PARP inhibitors for prostate cancer patients.
Therapy Innovation: Whether the identified gaps in post-Lu177 therapy options will accelerate development of new treatments for metastatic castration-resistant prostate cancer.